CAMPBELL, CA – (February 18, 2020) – Saama Technologies, Inc. (“Saama”), the number one AI clinical analytics platform company, announced today that it recently expanded its leadership team to include life science technology expert Jonathan Burr as Senior Vice President of Clinical Platform Strategy, and technology marketing leader Gregory T. Simpson as Vice President, Head of Marketing. Jonathan is responsible for growing client adoption of Saama’s existing products, and Greg is charged with building and strengthening the Saama brand. The announcement came at the start of the 11th Annual Summit for Clinical Ops Executives (SCOPE) meeting in Orlando.
“Jonathan and Greg’s vast, collective life science industry experience and impressive individual expertise in sales and marketing, respectively, enhance, compliment and extend the existing talent embodied in Saama’s leadership team,” said Suresh Katta, Saama’s Founder and CEO. “2020 is a year of strategic growth for Saama, and Jonathan and Greg will help fuel the expansion of our market share in furthering our position as the number one AI clinical analytics platform.”
Jonathan has spent two decades as a strategic, global life sciences industry thought leader, with a background in multiple technology domains, including clinical data management, biostatistics, pharmacovigilance, and regulatory. He joins Saama from Accenture Life Sciences, where he served as Managing Director in their London-based Accelerated Research & Development (R&D) Services practice, spearheading R&D technology offerings across Europe. He previously led the Accenture Life Sciences Cloud (ALSC) offering, had sales tenures at Oracle and the contract research organization PPD, and was in software development at Datatrial.
“I was drawn to Saama’s reputation as an innovative data analytics disrupter, and I am very excited to use my expertise for identifying life science technology trends and market opportunities to inspire customers with a vision and roadmap for leveraging Saama’s solutions to meet their clinical development needs,“ said Jonathan.
Greg leads Saama’s overall marketing strategy and execution, with responsibility for building and strengthening the Saama brand, supporting growth strategies, cultivating opportunities, and increasing demand for Saama’s solutions. Prior to joining Saama, Greg led an integrated marketing team at Medidata Solutions, where he built a marketing operations team and led product marketing for the Medidata Clinical Cloud. He previously served as Chief Marketing Officer for Frontwave, and his entrepreneurial experiences include founding a marketing consultancy and serving as the CEO of an internet startup. Greg also held executive marketing, product management, and sales positions at AT&T. Greg received an MBA in Marketing and an MS degree in International Business from Seton Hall University. He has a certification in Executive Leadership from Cornell University, and is currently pursuing a MicroMasters in Artificial Intelligence at Columbia University.
“This is a very dynamic time in Saama’s growth, and marketing has a great opportunity and responsibility to contribute to the company’s success by helping our customers understand how they can overcome the challenges inherent in clinical operations and revolutionize their trials with Saama solutions,” said Greg. “I am delighted that I have an opportunity at Saama to advance these important goals.”
About Saama Technologies, Inc.
Saama is the number one AI clinical analytics platform company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs. Ten of the top 20 pharmaceutical companies use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform. LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster.
Access Out-of-the-Box Features in 4 Weeks—Guaranteed.
Saama can put you on the fast track to clinical trial process innovation.